Peng G W
J Pharm Sci. 1984 Aug;73(8):1173-5. doi: 10.1002/jps.2600730840.
A procedure for the quantitative determination of adinazolam in plasma was developed. The drug, an N-demethylated metabolite, and an internal standard were extracted from basified plasma into ethyl acetate. After evaporation, the residue was dissolved in toluene which was washed with sodium hydroxide. The toluene was evaporated and the residue was dissolved in a mixture of acetonitrile, methanol, and water for chromatography. The concentrations of the drug and the metabolite were determined using reverse-phase liquid chromatography with UV detection at 254 nm. The assay methodology showed good peak height ratio-concentration linearity, precision, and accuracy and has been used to analyze plasma samples collected from human subjects after oral administration of adinazolam mesylate in compressed tablets. The low plasma background interferences allowed the quantitative determination of concentrations as low as approximately 5 ng/mL.
建立了一种定量测定血浆中阿地唑仑的方法。将该药物、一种N-去甲基代谢物和一种内标从碱化血浆中萃取到乙酸乙酯中。蒸发后，残渣溶于甲苯，并用氢氧化钠洗涤甲苯。蒸发甲苯，残渣溶于乙腈、甲醇和水的混合物中用于色谱分析。采用反相液相色谱法，在254nm处进行紫外检测，测定药物和代谢物的浓度。该分析方法具有良好的峰高比-浓度线性、精密度和准确度，已用于分析口服甲磺酸阿地唑仑压制片后从人体受试者采集的血浆样本。低血浆背景干扰使得能够定量测定低至约5 ng/mL的浓度。
